The essence of modern HPLC: Advantages, limitations, fundamentals, and opportunities

LCGC North America

Volumn 31, Issue 6, 2013, Pages 472-479

  Dong, Michael W ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885658743     PISSN: 15275949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. M.W. Dong, LCGC North Am. 31(4) 316-325 (2013).
2. Market Analysis and Perspectives Report for Analytical and Life Science Instruments Industry (Strategic Directions Inc., Los Angeles, California, 2012).
3. M.W. Dong, Modern HPLC for Practicing Scientists (Wiley, Hoboken, New Jersey, 2006).
4. L.R. Snyder, J.J. Kirkland, and J. W. Dolan, Introduction to Modern Liquid Chromatography, 3rd ed. (John Wiley & Sons, Hoboken, New Jersey, 2009).
5. Handbook of Pharmaceutical Analysis by HPLC, S. Ahuja and M.W. Dong, Eds. (Elsevier/Academic Press, 2005).
6. HPLC for Pharmaceutical Scientists, Y.V. Kazakevich and R. LoBrutto, Eds. (Wiley, Hoboken, New Jersey, 2007).
7. C.F. Poole, Essence of Chromatography (Elsevier Science, Amsterdam, The Netherlands, 2002).
8. Chromatography: A Science of Discovery, R.L. Wixom and C.L. Gehrke, Eds. (Wiley, Hoboken, New Jersey, 2010).
9. UHPLC in Life Sciences, D. Guillarme, J-L Veuthey, and R.M. Smith, Eds. (Royal Society of Chemistry, Cambridge, United Kingdom, 2012).
10. M. Swartz, M. Emmanuel, A. Awad, and D. Hartley, "Advances in HPLC Systems Technology" supplement to LCGC North Am. 27(4), 40-48 (2009).
11. Mass Spectrometry for Drug Discovery and Drug Development, W.A. Korfmacher, Ed. (Wiley, Hoboken, New Jersey, 2013).
12. J.E. MacNair, K.C. Lewis, and J.W. Jorgenson, Anal. Chem. 69, 983-989 (1997).
13. M.W. Dong, LCGC North Am. 25(7), 656-666 (2007).
14. N. Wu and A.M. Clausen, J. Sep. Sci. 30, 1167-1182 (2007).
15. D. Guillarme and M.W. Dong, Amer. Pharm. Rev., (2013) submitted.
16. M.W. Dong, D. Guillarme, S. Fekete, R. Rangelova, J. Richards, D. Prudhomme, and N.P. Chetwyn, J. Chromatogr. A. submitted.
17. L. Sannes, "Commercializing Biomarkers in Therapeutic and Diagnostic Applications-Overview, " Insight Pharma Report, May 2011.
18. A. Tessitore, A. Gaggiano, G. Cicciarelli, D. Verzella, D. Capece, M. Fischietti, F. Zazzeroni, and E. Alesse, Int. J. Proteomics2013, 1-15 (2013).
19. F.E. Regnier, LCGC North Am. 30(8), 622-623 (2012).
20. M. Hollmer, "2012's Top 10 Diagnostics Companies, " Fierce Medical Devices, November 27, 2012, http://www.fiercemedicaldevices.com/special-reports/top-10-diagnostics-companies.
21. J.D. Carroll, "The 15 best-selling drugs of 2012, " Fierce Pharma, October 9, 2012, http://www.fiercepharma.com/special-reports/15-best-selling-drugs-2012.
22. T. Zhang, J. Zhang, D. Hewitt, B. Tran, X. Gao, Z.J. Qiu, M. Tejada, H. Gazzano-Santoro, and Y-H. Kao, Anal. Chem. 84,7112-7123 (2012).
23. S. Fekete, M.W. Dong, T. Zhang, and D. Guillarme, J. Pharm. Biomed. Anal. submitted.